UvA-DARE (Digital Academic Repository)

Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease

Khor, C.C.; Davila, S.; Shimizu, C.; Sheng, S.; Matsubara, T.; Suzuki, Y.; Newburger, J.W.; Baker, A.; Burgner, D.; Breunis, W.; Kuijpers, T.; Wright, V.J.; Levin, M.; Hibberd, M.L.; Burns, J.C.

DOI

[10.1136/jmg.2010.086611](https://doi.org/10.1136/jmg.2010.086611)

Publication date

2011

Document Version

Final published version

Published in

Journal of Medical Genetics

[Link to publication](#)

Citation for published version (APA):

Khor, C. C., Davila, S., Shimizu, C., Sheng, S., Matsubara, T., Suzuki, Y., Newburger, J. W., Baker, A., Burgner, D., Breunis, W., Kuijpers, T., Wright, V. J., Levin, M., Hibberd, M. L., & Burns, J. C. (2011). Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. *Journal of Medical Genetics*, 48(7), 467-472. <https://doi.org/10.1136/jmg.2010.086611>

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

ORIGINAL ARTICLE

Genome-wide linkage and association mapping identify susceptibility alleles in *ABCC4* for Kawasaki disease

Chiea Chuen Khor,^{1,2} Sonia Davila,^{1,3} Chisato Shimizu,⁴ Stephanie Sheng,⁴ Tomoyo Matsubara,⁵ Yasuo Suzuki,⁶ Jane W Newburger,⁷ Annette Baker,⁷ David Burgner,⁸ Willemijn Breunis,^{9,10} Taco Kuijpers,^{9,10} Victoria J Wright,¹¹ Michael Levin,¹¹ Martin L Hibberd,^{1,2} Jane C Burns,⁴ on behalf of the US and International Kawasaki Disease Genetics Consortia*

► Additional tables and figures are published online only. To view these files please visit the journal online (<http://jmg.bmj.com>).

For numbered affiliations see end of article.

Correspondence to

Jane C Burns, Department of Pediatrics, University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0641, USA; jcburns@ucsd.edu

CCK, SD, MLH, and JCB contributed equally to this work.

*Members of both consortiums are listed in appendix 1.

Received 25 October 2010

Revised 27 March 2011

Accepted 28 March 2011

Published Online First

13 May 2011

ABSTRACT

Background Kawasaki disease (KD) is a self limited vasculitis in which host genetics plays a prominent role. To further the understanding of the role of host genetics in KD, a three-stage genetic study was conducted that began with a family linkage study and ultimately involved more than 3000 individuals to identify new genetic contributions to KD susceptibility.

Methods and results A 26-family linkage study followed by fine mapping was performed in a cohort of 1284 KD subjects and their family members (total 3248 individuals). Suggestive evidence of disease linkage (logarithm of odds (LOD) ≥ 3.0 , $p < 1.00 \times 10^{-4}$) was found for five genomic locations (Chr 3q, 4q, 10p, 13q, 21q). Two of these loci (Chr 4q and Chr 13q) overlapped with validated findings from a recent KD genome-wide association study. Fine mapping analysis revealed three single nucleotide polymorphisms (SNPs) in *ATP-binding cassette, subfamily C, member 4 (ABCC4)* underlying the Chr 13q linkage peak showing evidence of association to KD (lowest $p = 8.82 \times 10^{-5}$; combined OR 2.00, 95% CI 1.41 to 2.83). *ABCC4* is a multifunctional cyclic nucleotide transporter that stimulates the migratory capacity of dendritic cells. It is also a mediator of prostaglandin efflux from human cells and is inhibited by non-steroidal anti-inflammatory medications such as aspirin.

Conclusion These genetic data suggest that *ABCC4* could play a fundamental role in KD pathogenesis with effects on immune activation and vascular response to injury.

INTRODUCTION

Kawasaki disease (KD) is a systemic vasculitis of medium sized arteries primarily affecting children. The cause of the disease is unknown, and although many patients experience an uneventful recovery, up to 25% of untreated children will develop potentially fatal coronary arterial aneurysms. An infectious aetiology for KD has been suspected but the agent remains elusive.¹ Clues suggesting a possible genetic link to KD include strikingly different rates of occurrence in different ethnic groups (individuals of Asian descent are notably more susceptible), and higher-than-expected

concordance between sibling pairs.² Accordingly, a genome-wide association study (GWAS) of KD was performed and reported suggestive evidence of association ($p \sim 10^{-6}$) of two genes (*NAALADL2* and *ZFHX3*) with KD.³ Due to limited statistical power, the modest GWAS sample size (107 cases and 134 controls) precluded unequivocal detection of other KD susceptibility genes of smaller effect size and/or rarer risk allele frequencies.

We now utilise a combined linkage and association approach to identify other potential KD susceptibility genes which were not identified by the GWAS.

METHODS

KD was diagnosed according to the criteria of the American Heart Association,⁴ which include fever, together with at least four of the five classical diagnostic criteria:

1. Polymorphous erythematous rash
2. Non-purulent bilateral conjunctival injection
3. Oropharyngeal changes, including diffuse hyperaemia, strawberry tongue, and lip changes (eg, swelling, fissuring, erythema, bleeding)
4. Peripheral extremity changes, including erythema, oedema, induration, and desquamation
5. Non-purulent cervical lymphadenopathy

Children with at least 5 days of fever and at least two diagnostic criteria with echocardiographic findings of coronary artery damage during the acute and/or convalescent phases of KD were also included, as these coronary artery manifestations are pathognomonic for KD. Cases of incomplete KD, who have fever, <4 diagnostic criteria, and no coronary artery manifestations (who constitute approximately 15% of KD cases receiving clinical treatment), were excluded to maximise the homogeneity of the clinical phenotype.

In all cohorts, clinical and laboratory data were obtained directly from patient medical files and supplemented with parental questionnaires. Phenotypic data were reviewed in all cases by experienced pediatricians. Ethical approval was obtained from the appropriate national and regional institutional review boards for each study population.³ Informed consent and assent as appropriate were obtained from participating families.

Complex traits

Figure 1 Genome-wide linkage results. Genome-wide linkage results are shown, with the dotted line indicating maximum logarithm of odds (LOD) score (MLS)=3.

Linkage cohort

All families enrolled in the KD Genetics Study in the USA were asked regarding other affected family members and attempts were made to collect DNA samples on all individuals in the pedigree. Collaborators in Japan identified four families with more than one affected member. For the linkage cohort, 26 out of 30 pedigrees recruited were analysed (supplementary table 1, supplementary figure 1), as samples from both parents were available for the affected individuals.

Case-control cohort

This cohort was enrolled from the Netherlands and comprises 191 KD cases and 225 controls (416 individuals of European descent). All KD cases were identified by collaborating paediatricians and sent for cardiac evaluations and subsequent follow-up by one of the co-authors (TWK; more information on the clinical characteristics of subjects can be found in supplementary table 2). The controls were unrelated, adult blood donors living in the same geographical area. Ethnicity was determined by self report or parental report on behalf of the child.

Family based cohorts

The cohorts used for family based association testing included 715 complete parent affected offspring trios (2145 individuals) plus an additional 378 cases with either one (n=191) or no (n=187) parents providing a DNA sample. An unaffected sibling was also included in 198 of the families. Subjects were recruited from Australia, the Netherlands, USA, and UK. These cases were identified from paediatric hospital databases, from parental support groups, and through media releases. More detailed information can be found in supplementary table 2.

Study design

We used a three-stage study design to evaluate the contribution of genetic factors to KD susceptibility. Stage 1 was a genetic linkage study analysing 26 KD pedigrees (supplementary figure 1). Stage 2 involved searching for regions of overlap between linkage peaks (logarithm of odds (LOD) ≥ 3) observed in KD pedigrees and replicated associations reported in the previous GWAS.³ Stage 3 involved fine-scale mapping of the strongest associated region (stage 2 $p < 1.00 \times 10^{-4}$) identified in stage 2. This fine-scale mapping was carried out in 191 KD cases, 225 controls, and 715 complete case-parent trios.

Genotyping methods

DNA samples from the linkage study were genotyped using the Illumina Linkage 12 panel (<http://www.illumina.com>; 6089 single nucleotide polymorphisms (SNPs) spaced evenly throughout the human genome). Follow-up genotyping was performed using the Sequenom Mass-Array iPLEX platform (<http://www.sequenom.com>).

Figure 2 Association scan of the 1-LOD-drop region underlying Chr 13q. Top panel: Linkage scan results. Middle panel: Fine mapping association results. Boxes represent genes. The genes, from left to right are: *ABCC4*, *CLDN10*, *DZIP1*, *DNAJC3*, *UGCG2*, *HS6ST3*, *MBNL2*, *FARP1*, *DOCK9*, and *VGCNL1*. Bottom panel: Fine mapping association results in the context of the 395 single nucleotide polymorphisms (SNPs) typed in the genome-wide association study (GWAS). ◆ denotes meta-p value of rs7320375, ▲ for rs7986087, and # for rs7329490. * denotes the original GWAS p values for rs7320375 and rs7986087.

Statistical analysis

Linkage analysis was performed using the MERLIN statistical package, as previously described (<http://www.sph.umich.edu/csg/abecasis/merlin/download/>).⁵ The Kong and Cox non-parametric, exponential model was chosen to allow sharing of a small number of large effect alleles among a small number of families to be more reliably detected.⁶ The non-parametric model is unguided (model-free) and does not assume any given mode of inheritance. This is appropriate since the mode of inheritance of the susceptibility loci for KD is unknown and not necessarily the same for each locus. The Kong and Cox algorithm performs multipoint calculations and hence allows the full utilisation of the information available on descent and the inheritance pattern at every locus. An LOD score of 3 accompanied by $p < 1.00 \times 10^{-4}$ was considered suggestive evidence of linkage.⁷

For the case-control study, tests of disease marker association were performed using the model-free allelic test which compares the difference in SNP minor allele frequency between KD

Table 1 Analysis by transmission disequilibrium testing of eight single nucleotide polymorphisms (SNPs) within the 1-LOD drop interval defining the Chr 13q linkage region significant at $p < 0.01$ from the genome-wide association study (GWAS)

SNP	Chr band	Position	Gene	GWAS study				GWAS study + all remaining samples*		
				Cases	Controls	p Value	OR	p Value	OR	95% CI
rs7320375	13q32.1	94709934	ABCC4	0.058	0.020	0.0059	2.97	0.000088	2.00	1.41 to 2.83
rs7986087	13q32.1	94713746	ABCC4	0.054	0.020	0.0062	2.74	0.0003	1.98	1.38 to 2.83
rs11070146	13q32.1	95098788	DZIP1	0.116	0.051	0.0015	2.45	0.04	1.25	1.01 to 1.55
rs11070147	13q32.1	95098938	DZIP1	0.117	0.051	0.0014	2.47	0.07	1.22	0.99 to 1.51
rs285032	13q32.1	97584534	FARP1	0.43	0.59	0.0004	0.52	0.53	0.96	0.84 to 1.10
rs9513515	13q32.3	98394451	DOCK9	0.471	0.408	0.0023	1.30	0.20	1.10	0.95 to 1.27
rs9557096	13q32.3	98401880	DOCK9	0.471	0.409	0.0031	1.29	0.09	1.13	0.98 to 1.30
rs4772360	13q33.1	1.01E+08	VGCNL1	0.116	0.135	0.0080	0.84	0.18	0.89	0.75 to 1.06

*1177 KD subjects and associated family members, total=3010 subjects.

patients and controls. The p value was computed from an accompanying χ^2 statistic (with 1 degree of freedom) which measures the significance of the difference in allele frequencies observed between cases and controls. The calculated OR is modelled from the allelic test, which represents the increase in risk of KD per copy of the risk allele. For family based cohorts, tests of disease marker association was performed using the transmission-disequilibrium test (TDT)⁸ as implemented in the PLINK software (<http://pngu.mgh.harvard.edu/purcell/plink/>).⁹

The TDT statistic has a χ^2 distribution and is expressed as $\chi^2 = (T - U)^2 / (T + U)$ whereby T is the total number of times the risk allele was transmitted and U is the number of times the risk allele was not transmitted. Transmissions are only scored from heterozygous parents to affected offspring. Only complete parent-offspring trios and unambiguous transmissions were scored with the test.

For meta-analysis, data from all three cohorts were pooled and common odds ratios (ORs) across all individuals were calculated

Table 2 Fine mapping results in all samples for the Chr 13q linkage peak

Chr	SNP	Position	191 cases and 225 controls				715 complete trios				Combined analysis		
			F_A	F_U	p Value	OR	T	U	p Value	OR	p Value	OR	95% CI
13	rs2274407	94657036	0.087	0.064	0.22	1.38	120	93	0.064	1.29	0.028	1.31	1.03 to 1.66
13	rs11568658	94661009	0.029	0.013	0.11	2.22	39	62	0.022	0.63	0.12	0.75	0.52 to 1.08
13	rs4148437	94697355	0.36	0.35	0.83	1.03	278	296	0.45	0.94	0.59	0.96	0.83 to 1.11
13	rs9556466	94698072	0.36	0.34	0.64	1.07	278	284	0.80	0.98	0.98	1.00	0.87 to 1.16
13	rs4148434	94701436	0.39	0.36	0.35	1.15	301	325	0.34	0.93	0.74	0.98	0.85 to 1.12
13	rs9590218	94704300	0.19	0.17	0.54	1.12	201	211	0.62	0.95	0.88	0.99	0.83 to 1.17
13	rs12584649	94705086	0.19	0.17	0.57	1.11	203	206	0.88	0.99	0.89	1.01	0.85 to 1.20
13	rs7321807	94706712	0.034	0.011	0.022	3.17	41	36	0.57	1.14	0.17	1.34	0.89 to 2.02
13	rs9561820	94708300	0.013	0.004	0.17	3.00	39	47	0.39	0.83	0.61	0.90	0.60 to 1.36
13	rs7320375	94709934	0.058	0.018	0.0021	3.38	71	40	0.0033	1.78	8.8×10^{-5}	2.00	1.41 to 2.83
13	rs4148433	94710538	0.032	0.011	0.037	2.92	41	35	0.49	1.17	0.16	1.35	0.89 to 2.04
13	rs7986087	94713746	0.052	0.018	0.0058	3.05	68	38	0.0036	1.79	3.0×10^{-4}	1.98	1.38 to 2.83
13	rs7329490	94714754	0.042	0.018	0.035	2.45	69	39	0.0039	1.77	5.8×10^{-4}	1.87	1.31 to 2.68
13	rs4148427	94723675	0.041	0.016	0.028	2.66	42	36	0.50	1.17	0.12	1.37	0.92 to 2.05
13	rs4773867	94728621	0.15	0.11	0.060	1.48	167	147	0.26	1.14	0.066	1.20	0.99 to 1.46
13	rs9524885	94733590	0.30	0.25	0.12	1.28	267	255	0.60	1.05	0.21	1.10	0.95 to 1.28
13	rs4773872	94737932	0.22	0.15	0.012	1.57	181	191	0.60	0.95	0.42	1.08	0.90 to 1.28
13	rs871052	94748741	0.44	0.41	0.43	1.12	337	298	0.12	1.13	0.084	1.13	0.98 to 1.29
13	rs868853	94753077	0.09	0.06	0.094	1.56	109	96	0.36	1.14	0.11	1.22	0.96 to 1.56
13	rs4773905	94881647	0.29	0.27	0.48	1.12	274	286	0.61	0.96	0.93	0.99	0.86 to 1.15
13	rs3843691	95128732	0.43	0.45	0.57	0.92	326	317	0.72	1.03	0.96	1.00	0.88 to 1.15
13	rs1537030	95343290	0.45	0.46	0.87	0.98	279	308	0.23	0.91	0.28	0.93	0.81 to 1.06
13	rs1411889	96331433	0.40	0.43	0.42	0.89	299	302	0.90	0.99	0.61	0.96	0.84 to 1.11
13	rs8001181	97409107	0.45	0.43	0.69	1.06	321	321	1	1	0.85	1.01	0.89 to 1.16
13	rs12583114	97561905	0.32	0.30	0.58	1.09	280	272	0.73	1.03	0.56	1.04	0.90 to 1.21
13	rs9634510	97572905	0.25	0.24	0.67	1.07	237	237	1	1	0.84	1.02	0.87 to 1.19
13	rs285081	97574397	0.39	0.45	0.11	0.80	345	314	0.23	1.10	0.76	1.02	0.89 to 1.17
13	rs285083	97576174	0.097	0.060	0.042	1.70	111	121	0.51	0.92	0.74	1.04	0.83 to 1.31
13	rs206209	97580687	0.54	0.43	0.0023	1.53	300	358	0.024	0.84	0.64	0.96	0.85 to 1.11
13	rs172245	97582132	0.48	0.40	0.036	1.35	293	344	0.043	0.85	0.45	0.95	0.83 to 1.09
13	rs285030	97583690	0.51	0.41	0.0047	1.49	300	353	0.038	0.85	0.66	0.97	0.85 to 1.11
13	rs285031	97584032	0.19	0.18	0.90	1.02	172	222	0.012	0.77	0.029	0.82	0.69 to 0.98
13	rs285033	97587810	0.19	0.15	0.11	1.34	198	204	0.76	0.97	0.63	1.04	0.88 to 1.24
13	rs285034	97588194	0.068	0.051	0.28	1.37	63	81	0.13	0.78	0.45	0.90	0.67 to 1.19
13	rs10508035	97588800	0.103	0.092	0.59	1.14	130	133	0.85	0.98	0.92	1.01	0.82 to 1.25

F_A, minor allele frequency in KD cases; F_U, minor allele frequency in controls; SNP, single nucleotide polymorphism; T, number of times the minor allele was transmitted; U, number of times the minor allele was un-transmitted.

Complex traits

Table 3 Genotype distributions of the three *ABCC4* single nucleotide polymorphisms (SNPs) in cases and controls

Genotype	Cases							
	Dutch		UK + Australia		All cases		Controls	
	n	%	n	%	n	%	n	%
a) rs7986087								
11	173	90.58	240	87.59	413	88.8	217	95.44
12	16	8.38	31	11.31	47	10.1	8	3.56
22	2	1.05	3	1.09	5	1.1	0	0
Total	191		274		465		225	
b) rs7320375								
11	171	89.53	240	87.59	411	88.4	217	96.44
12	18	9.42	31	11.31	49	10.5	8	3.56
22	2	1.05	3	1.09	5	1.1	0	0
Total	191		274		465		225	
c) rs7329490								
11	175	92.59	250	87.72	425	89.7	217	96.44
12	12	6.35	32	11.23	44	9.3	8	3.56
22	2	1.06	3	1.05	5	1.1	0	0
Total	189		285		474		225	

Cases from the US cohorts were not included for this analysis due to the low proportion of individuals of European descent in these cohorts.

using the inverse variance method.¹⁰ The meta-p value was calculated using Fisher's combined probability test, as previously described.³ This method of meta-analysis combines p values from several independent cohorts into one test statistic (X^2) using the formula defined by

$$X^2 = -2 \sum_{i=1}^k \log_e(p_i),$$

whereby p_i is the p value for the i^{th} independent cohort. The number of degrees of freedom is 2k.

The significance of the meta-p values was evaluated in the context of 429 independent tests (395 from the GWAS and 34 from fine mapping; see Results), and meta-p<0.00012 was considered to be significant experiment-wide. All p values reported here are two-tailed.

RESULTS

The results of the genome-wide linkage analysis are displayed in figure 1 (regions showing a nominal LOD ≥ 2.0 are included in supplementary table 3). Five chromosomal segments (Chr 3q, 4q, 10p, 13q, 21q) showed suggestive evidence of linkage to KD (figure 1 and supplementary figure 2; LOD score ≥ 3.0 , corresponding to $p \leq 1.0 \times 10^{-4}$). We then examined data from our previous GWAS³ for validated SNPs (SNPs which were associated in both the GWAS and replication study) underlying the

five linkage peaks. Two such SNPs were found underlying two of the five peaks (rs16869859 with $p=0.00012$ underlying Chr 4q, and rs285032 with $p=1.7 \times 10^{-5}$ underlying Chr 13q) (supplementary table 4).

We chose Chr 13q for in-depth assessment because the statistical evidence of association exceeded the pre-set threshold of $p < 10^{-4}$ and was much stronger than the association to Chr 4q.

By first systematically examining genotype data from the GWAS³ for SNP coverage within the 1-LOD drop interval defining the Chr 13q linkage region (between genomic positions 94.46 Mb and 101 Mb, figure 2), we identified 395 genotyped SNPs that passed quality control (see supplementary methods). From these 395 SNPs, we observed an excess of SNPs ($n=8$) showing association at $p < 0.01$ in the GWAS ($N=107$ cases and 134 controls, table 1) compared to chance alone ($n=4$). When these eight SNPs were genotyped in all remaining samples excluding the GWAS samples, ($N=1177$ KD cases within a total of 3010 subjects), two SNPs (rs7986087 and rs7320375) within *ABCC4* retained evidence of significant association with KD (table 1).

We then proceeded to fine map the region delineated by the two SNPs within *ABCC4* in all available KD subjects and controls samples (191 KD subjects, 225 controls, and 715 KD case-parent trios), as well as to exclude the involvement of the region around rs285032 (near *FARP1*) more definitively. This was done by genotyping an additional 34 SNPs within the *ABCC4* and *FARP1* regions (table 2). Fine mapping revealed a third SNP within *ABCC4* (rs7329490), located <5000 base pairs away from the originally associated SNPs (rs7986087 and rs7320375) which also showed suggestive evidence of association with KD ($p=5.8 \times 10^{-4}$). In contrast, no association with KD was observed for all 11 SNPs genotyped in the vicinity of *FARP1* (table 2, figure 2). The overall/gene-wide extent of linkage disequilibrium was moderately low within *ABCC4*.

However, the three associated SNPs were in very tight LD ($r^2 > 0.95$), confined within a block 7000 bp in size (supplementary figure 3), thus suggesting this 7 Kb block to be the region of association where the causative variant(s) may lie.

Combining the data from all available samples, we found evidence of association with KD for three *ABCC4* SNPs (meta- $p=5.8 \times 10^{-4}$ to 8.8×10^{-5} , and per-allele ORs=1.87 to 2.00, table 2, figure 2). Detailed genotype analysis of all KD cases and the population based controls for all three SNPs revealed that individuals carrying a single risk allele were significantly over-represented among the KD cases, and almost all individuals homozygous for the risk allele were KD cases (table 3). Homozygosity for any one SNP was linked to homozygosity at the other two loci. Haplotype analysis between the three SNPs did not reveal levels of significance exceeding that observed with single marker analysis, likely due to their very strong inter-marker LD.

DISCUSSION

We utilised three distinct but complementary study approaches to search for disease genes. In the first stage, linkage analysis tracked sharing of large chromosomal segments between family members affected with KD (see supplementary figure 4 for informative families significantly contributing to the LOD score), assisting in identifying 'regions of interest' for further detailed enquiry. The finer resolution of the case-control approach allowed comparison of allele frequencies of genetic variants between KD cases and controls. While having greater statistical power to detect disease associations, case-control

Table 4 Independent statistical evidence summarising support for the Chr 13q locus at *ABCC4*

	N	Analysis	p Value
Linkage results	26 pedigrees	Linkage	5.41×10^{-5}
LD mapping in case-controls	191 cases, 225 controls	Case-control	0.0021
LD mapping in Trios	715 complete trios	TDT	0.0033
All LD mapping results		Fisher's test	8.8×10^{-5}
Addition of WTCCC controls	4674	Case-control	$< 1.0 \times 10^{-7}$

WTCCC controls were added to the case-control sample and re-analysed.

LD, linkage disequilibrium; TDT, transmission disequilibrium test; WTCCC, Wellcome Trust Case Control Consortium.

studies potentially suffer from biases such as population stratification and phenotype misclassification.

Fortunately, KD is rare and the proportion of controls with unrecognised KD will be very low. The transmission disequilibrium test is substantially more robust compared to the case-control approach in that it protects against population stratification by scoring transmissions only from heterozygous parents to affected offspring. Consistency of results observed across all three study methodologies confirmed disease association independent of linkage signals.

Nonetheless, our study suffers from limitations. The sample size for the linkage screen was very modest ($N=26$ pedigrees analysed); in light of this, statistical power was limited and other significant disease loci with smaller effect sizes compared to that observed at *ABCC4* (per-allele $OR=2.0$) could have been missed. This was likely the case for *NAALADL2* and *ZFXH3*, two significantly associated genes in the GWAS (per-allele $OR=1.43$ and 1.56 , respectively) where no major evidence of linkage in their chromosomal segments was detected in these 26 families. Thus, our linkage study was powered only to detect moderately large genetic effects reliably exceeding experiment-wide thresholds of significance, and a larger sample of pedigrees will be required for detection of more modestly contributing alleles (eg, $OR \sim 1.5$).

Turning to the experimental findings, we noted that in the case-control association study, individuals homozygous for the risk allele of the three *ABCC4* SNPs were only found among the KD cases, with none observed in our initial Dutch ($n=225$) and HapMap CEU controls ($n=60$). Only by adding controls from the WTCCC2 ($n=4674$), which had data for SNP rs7986087 and thus allowed a total of 4959 controls to be examined, were we able to observe homozygosity ($n=4$, frequency of homozygous mutants=0.08%). Thus, the estimate of the odds of disease conferred by homozygosity is 8.68 (95% CI 1.94 to 36.9; $p<10^{-7}$, table 4, supplementary table 5). We noted that the minor allele frequency of *ABCC4* rs7986087 was not significantly different across all three Caucasian control groups (Dutch MAF=1.8%, $n=225$, HapMap CEU=5.8%, $n=60$, and WTCCC2=2.3%, $n=4674$). Strikingly, homozygosity for the risk allele at the three SNPs was shared across the same individuals, in direct keeping with observations in the linkage study, lending credence that convergence of linkage and association signals could be used to identify disease genes. One other phenotype which showed such consistency between linkage, family based, and association studies is type 2 diabetes, where the gene *TCF7L2*¹¹ ($RR=1.45-1.5$, current meta-p on all known cohorts $<10-100$) was identified from an original linkage signal ($LOD=2.79$).¹² Future studies will focus on re-sequencing within the associated region of *ABCC4* to identify the causative variant(s).

ABCC4 (also known as MRP4; multi-drug resistance protein 4) belongs to a family of ATP binding cassette transporters. It has been shown to be crucial in the release of prostaglandins from cells; in particular, *ABCC4* mediates the efflux of PGE1 and PGE2,¹³ a function that is inhibited by non-steroidal anti-inflammatory agents in vitro.¹⁴⁻¹⁶ Our genetic findings thus suggest a role for *ABCC4*, a protein responsible for prostaglandin transport and augmentation of inflammation, in the pathogenesis of KD. Re-sequencing of *ABCC4* is warranted to better understand the risk alleles associated with KD susceptibility. *ABCC4* is a large gene (282 Kb) and thus re-sequencing would need to be targeted to regions of highest disease association. As carriers of these *ABCC4* genetic variants have on average, a twofold per-allele increased risk of KD, knowledge of this gene's function in KD may provide valuable insight into disease pathogenesis.

Author affiliations

- ¹Division of Infectious Diseases, Genome Institute of Singapore, Singapore
- ²Department of Epidemiology and Public Health, Centre for Molecular Epidemiology, National University of Singapore, Singapore
- ³Division of Human Genetics, Genome Institute of Singapore, Singapore
- ⁴Department of Pediatrics, University of California San Diego School of Medicine and Rady Children's Hospital, San Diego, California, USA
- ⁵Department of Pediatrics, Juntendo University Graduate School of Medicine, Chiba, Japan
- ⁶Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan
- ⁷Department of Cardiology, Children's Hospital Boston, Boston, Massachusetts, USA
- ⁸Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville Victoria, Australia
- ⁹Department of Paediatric Hematology, Emma Children's Hospital, Academic Medical Center (AMC), Immunology and Infectious Diseases, Amsterdam, The Netherlands
- ¹⁰Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory, University of Amsterdam, Amsterdam, The Netherlands
- ¹¹Imperial College London, Department of Pediatrics, Division of Medicine, London, UK

Acknowledgements We thank all individuals with Kawasaki disease and their families for participating in this study. We thank Wee-Yang Meah, Hong-Boon Toh, Xiaoyin Chen, Khai-Koon Heng, Chang-Hua Wong, Dennis EK Tan, Nicholas JW Tay, Poh-Ling Ng, Sherrina HY Chen, and Sigeeta Rajaram for technical support and expertise. This work supported in part by a grant (HL69413) from the National Institutes of Health, National Heart, Lung, Blood Institute (to JCB), the Raine Medical Research Foundation, the Ada Bartholomew Medical Research Trust, the University of Western Australia, the National Heart Foundation of Australia, and the Agency for Science, Technology and Research, Singapore.

Competing interests None.

Ethics approval Ethical approval was obtained from the appropriate national and regional institutional review boards for each study population.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Rowley AH, Baker SC, Orenstein JM, Shulman ST. Searching for the cause of Kawasaki disease—cytoplasmic inclusion bodies provide new insight. *Nat Rev Microbiol* 2008;**6**:394–401.
2. Onouchi Y. Molecular genetics of Kawasaki disease. *Pediatr Res* 2009;**65**:46R–54R.
3. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, Ling L, Wright VJ, Thalamuthu A, Odam M, Shimizu C, Burns JC, Levin M, Kuijpers TW, Hibberd ML. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. *PLoS Genet* 2009;**5**:e1000319.
4. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics* 2004;**114**:1708–33.
5. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin—rapid analysis of dense genetic maps using sparse gene flow trees. *Nat Genet* 2002;**30**:97–101.
6. Kong A, Cox NJ. Allele-sharing models: LOD scores and accurate linkage tests. *Am J Hum Genet* 1997;**61**:1179–88.
7. Nyholt DR. All LODs are not created equal. *Am J Hum Genet* 2000;**67**:282–8.
8. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). *Am J Hum Genet* 1993;**52**:506–16.
9. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;**81**:559–75.
10. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat Genet* 2000;**26**:76–80.
11. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadóttir A, Styrkarsdóttir U, Magnusson KP, Walters GB, Palsdóttir E, Jonsdóttir T, Gudmundsdóttir T, Gylfason A, Saemundsdóttir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdóttir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. *Nat Genet* 2006;**38**:320–3.
12. Reynisdottir I, Thorleifsson G, Benediktsson R, Sigurdsson G, Emilsson V, Einarsdóttir AS, Hjorleifsdóttir EE, Orlygssdóttir GT, Bjornsdóttir GT, Saemundsdóttir J, Halldorsson S, Hrafnkelsdóttir S, Sigurjonsdóttir SB, Steinsdóttir S, Martin M, Kochan JP, Rhees BK, Grant SF, Frigge ML, Kong A, Gudnason V, Stefansson K, Gulcher JR.

Complex traits

- Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34-q35.2. *Am J Hum Genet* 2003;**73**:323–35.
13. **Reid G**, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. *Proc Natl Acad Sci U S A* 2003;**100**:9244–9.
 14. **Nozaki Y**, Kusuhashi H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, Sugiyama Y. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. *J Pharmacol Exp Ther* 2007;**322**:1162–70.
 15. **Jedlitschky G**, Tirschmann K, Lubenow LE, Nieuwenhuis HK, Akkerman JW, Greinacher A, Kroemer HK. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. *Blood* 2004;**104**:3603–10.
 16. **El-Sheikh AA**, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. *J Pharmacol Exp Ther* 2007;**320**:229–35.

APPENDIX 1

US Kawasaki Genetics Consortium

Jane W Newburger, Annette L Baker, Cardiology; Boston Children's Hospital, Boston, MA; Anne H Rowley, Stanford T Shulman, Pediatrics, Northwestern University Feinberg School of Medicine, Children's Memorial Hospital, Chicago, IL; Wilbert

Mason, Pediatrics, Masato Takahashi, Cardiology, Los Angeles Children's Hospital, Los Angeles, CA; Marian E Melish, Pediatrics, Kaplani Children's Hospital, Honolulu, Hawaii; Adriana H Tremoulet, University of California San Diego.

Members of the International Kawasaki Disease Genetics Consortium

Australia: Miranda Odam, Frank Christiansen, University of Western Australia, Campbell Witt, Royal Perth Hospital, Perth, Western Australia; Paul Goldwater, The Women's & Children's Hospital, South Australia; Nigel Curtis, Royal Children's Hospital, Victoria; Pamela Palasanthiran, John Ziegler, Sydney Children's Hospital, Randwick, New South Wales; Michael Nissan, Royal Children's Hospital, Clare Nourse, Mater Hospital, Queensland.

The Netherlands: Irene M Kuipers, Jaap J Ottenkamp, Judy Geissler, Maarten Biezeveld, Emma Children's Hospital, Academic Medical Center; Luc Filippini, Juliana Children's Hospital, The Hague.

Singapore: Ling Ling.

UK: Paul Brogan, Nigel Klein, Vanita Shah, Michael Dillon, The Institute of Child Health, London; Robert Booy, Delane Shingadia, Anu Bose, Thomas Mukasa, Royal London Hospital, London; Robert Tulloh, Bristol Royal Hospital for Children, Bristol; Colin Michie, Ealing Hospital, London.

Journal of Medical Genetics online

Visit **JMG online** for free editor's choice articles, online archive, email alerts, blogs or to submit your paper. Keep informed and up to date by registering for electronic table of contents at jmg.bmj.com.

Genome-wide linkage and association mapping identify susceptibility alleles in *ABCC4* for Kawasaki disease

Chiea Chuen Khor, Sonia Davila, Chisato Shimizu, et al.

J Med Genet 2011 48: 467-472 originally published online May 13, 2011

doi: 10.1136/jmg.2010.086611

Updated information and services can be found at:

<http://jmg.bmj.com/content/48/7/467.full.html>

These include:

References

This article cites 16 articles, 5 of which can be accessed free at:

<http://jmg.bmj.com/content/48/7/467.full.html#ref-list-1>

Article cited in:

<http://jmg.bmj.com/content/48/7/467.full.html#related-urls>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Dermatology](#) (213 articles)

[Vascularitis](#) (2 articles)

[Immunology \(including allergy\)](#) (502 articles)

[Molecular genetics](#) (1094 articles)

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>